Prediagnostic breast milk DNA methylation alterations in women who develop breast cancer

Prior candidate gene studies have shown tumor suppressor DNA methylation in breast milk related with history of breast biopsy, an established risk factor for breast cancer. To further establish the utility of breast milk as a tissue-specific biospecimen for investigations of breast carcinogenesis, we measured genome-wide DNA methylation in breast milk from women with and without a diagnosis of breast cancer in two independent cohorts. DNA methylation was assessed using Illumina HumanMethylation450k in 87 breast milk samples. Through an epigenome-wide association study we explored CpG sites associated with a breast cancer diagnosis in the prospectively collected milk samples from the breast that would develop cancer compared with women without a diagnosis of breast cancer using linear mixed effects models adjusted for history of breast biopsy, age, RefFreeCellMix cell estimates, time of delivery, array chip and subject as random effect. We identified 58 differentially methylated CpG sites associated with a subsequent breast cancer diagnosis (q-value \u3c0.05). Nearly all CpG sites associated with a breast cancer diagnosis were hypomethylated in cases compared with controls and were enriched for CpG islands. In addition, inferred repeat element methylation was lower in breast milk DNA from cases compared to controls, and cases exhibited increased estimated epigenetic mitotic tick rate as well as DNA methylation age compared with controls. Breast milk has utility as a biospecimen for prospective assessment of disease risk, for understanding the underlying molecular basis of breast cancer risk factors and improving primary and secondary prevention of breast cancer

An exploratory study looking at the relationship marketing techniques used in the music festival industry

There are current issues and trends in the music festival market, which may affect the success of an event, and market saturation is at the forefront of these issues. Previous literature, maintaining the need for a marketing approach to festivals, identifi es the need for maintaining strong stakeholder relationships in order to succeed in a business environment; attention has been focused to the theory of relationship marketing (RM) because of the recognition that this practice is complementary to the marketing of festivals. The very nature of the music festival as an annual, usually, 4-day event means that effective marketing is needed to keep connections with the consumer throughout the year. This article focuses on the RM techniques utilised within the music festival industry from the viewpoint of the festival organiser in an attempt to establish how festival organisations value and monitor organisational relationships. This article explores the extent to which these relationships are valued and managed; furthermore, the variations between these intricate relationships are considered by focusing on those held with the organisation ’ s consumers and sponsors, the results of which have provided the ability to establish the importance and relevance of RM to the industry and further identify the marketing communication methods employed to establish and maintain such relationships. In-depth, convergent interviews have been conducted with a segment of music festival organisers from a range of events. The results have been integrated with the study of current literature to best exemplify these issues. It has been established that RM has a strong role in today ’ s commercial and independent music festival industry; technological advances are enabling the organiser to support online relationships further and increase consumer loyalty. There is a need to expand the research further because of the complexity of organisational relationships and the varying categories of festivals

Plasma lipid profiles change with increasing numbers of mild traumatic brain injuries in rats

Mild traumatic brain injury (mTBI) causes structural, cellular and biochemical alterations which are difficult to detect in the brain and may persist chronically following single or repeated injury. Lipids are abundant in the brain and readily cross the blood-brain barrier, suggesting that lipidomic analysis of blood samples may provide valuable insight into the neuropathological state. This study used liquid chromatography-mass spectrometry (LC-MS) to examine plasma lipid concentrations at 11 days following sham (no injury), one (1×) or two (2×) mTBI in rats. Eighteen lipid species were identified that distinguished between sham, 1× and 2× mTBI. Three distinct patterns were found: (1) lipids that were altered significantly in concentration after either 1× or 2× F mTBI: cholesterol ester CE (14:0) (increased), phosphoserine PS (14:0/18:2) and hexosylceramide HCER (d18:0/26:0) (decreased), phosphoinositol PI(16:0/18:2) (increased with 1×, decreased with 2× mTBI); (2) lipids that were altered in response to 1× mTBI only: free fatty acid FFA (18:3 and 20:3) (increased); (3) lipids that were altered in response to 2× mTBI only: HCER (22:0), phosphoethanolamine PE (P-18:1/20:4 and P-18:0/20:1) (increased), lysophosphatidylethanolamine LPE (20:1), phosphocholine PC (20:0/22:4), PI (18:1/18:2 and 20:0/18:2) (decreased). These findings suggest that increasing numbers of mTBI induce a range of changes dependent upon the lipid species, which likely reflect a balance of damage and reparative responses

Altered gut microbiome in Parkinson\u27s disease and the influence of lipopolysaccharide in a human α-synuclein over-expressing mouse model

The interaction between the gut microbiota and alpha-synuclein (αSyn) aggregation in Parkinson’s disease (PD) is receiving increasing attention. The objective of this study was to investigate gut microbiota, and effects of an inflammatory lipopolysaccharide (LPS) trigger in a human αSyn over-expressing mouse model of PD (Thy1-αSyn). Stool samples from patients with confirmed PD and Thy1-αSyn mice were analyzed using 16S ribosomal RNA sequencing. Compared to healthy controls, the relative abundance of mucin-degrading Verrucomicrobiae and LPS-producing Gammaproteobacteria were greater in PD patients. In mice, the abundance of Gammaproteobacteria was negligible in both Thy1-αSyn and wild-type (WT) animals, while Verrucomicrobiae were reduced in Thy1-αSyn mice. The effect of LPS on intestinal barrier function was investigated in vitro using intestinal epithelial (IEC-6) cells, and in vivo via administration of LPS in drinking water to Thy1-αSyn mice. Acute exposure to LPS in vitro resulted in a reduction and altered distribution of the tight junction markers ZO-1 and e-Cadherin around the cell membrane in IEC-6 cells, as shown by immunohistochemistry. LPS administration in Thy1-αSyn mice resulted in the emergence of early motor manifestations at 10 weeks, compared to untreated mice who were still asymptomatic at this age. This study reaffirms that an altered microbiome exists in patients with PD, and supports the notion of a proinflammatory gut microbiome environment as a trigger for PD pathogenesis

THE ELEVENTH AND TWELFTH DATA RELEASES OF THE SLOAN DIGITAL SKY SURVEY: FINAL DATA FROM SDSS-III

Citation: Alam, S., Albareti, F. D., Prieto, C. A., Anders, F., Anderson, S. F., Anderton, T., . . . Zhu, G. T. (2015). THE ELEVENTH AND TWELFTH DATA RELEASES OF THE SLOAN DIGITAL SKY SURVEY: FINAL DATA FROM SDSS-III. Astrophysical Journal Supplement Series, 219(1), 27. doi:10.1088/0067-0049/219/1/12The third generation of the Sloan Digital Sky Survey (SDSS-III) took data from 2008 to 2014 using the original SDSS wide-field imager, the original and an upgraded multi-object fiber-fed optical spectrograph, a new near-infrared high-resolution spectrograph, and a novel optical interferometer. All of the data from SDSS-III are now made public. In particular, this paper describes Data Release 11 (DR11) including all data acquired through 2013 July, and Data Release 12 (DR12) adding data acquired through 2014 July (including all data included in previous data releases), marking the end of SDSS-III observing. Relative to our previous public release (DR10), DR12 adds one million new spectra of galaxies and quasars from the Baryon Oscillation Spectroscopic Survey (BOSS) over an additional 3000 deg(2) of sky, more than triples the number of H-band spectra of stars as part of the Apache Point Observatory (APO) Galactic Evolution Experiment (APOGEE), and includes repeated accurate radial velocity measurements of 5500 stars from the Multi-object APO Radial Velocity Exoplanet Large-area Survey (MARVELS). The APOGEE outputs now include the measured abundances of 15 different elements for each star. In total, SDSS-III added 5200 deg(2) of ugriz imaging; 155,520 spectra of 138,099 stars as part of the Sloan Exploration of Galactic Understanding and Evolution 2 (SEGUE-2) survey; 2,497,484 BOSS spectra of 1,372,737 galaxies, 294,512 quasars, and 247,216 stars over 9376 deg(2); 618,080 APOGEE spectra of 156,593 stars; and 197,040 MARVELS spectra of 5513 stars. Since its first light in 1998, SDSS has imaged over 1/3 of the Celestial sphere in five bands and obtained over five million astronomical spectra.Additional Authors: Berlind, A. A.;Beutler, F.;Bhardwaj, V.;Bird, J. C.;Bizyaev, D.;Blake, C. H.;Blanton, M. R.;Blomqvist, M.;Bochanski, J. J.;Bolton, A. S.;Bovy, J.;Bradley, A. S.;Brandt, W. N.;Brauer, D. E.;Brinkmann, J.;Brown, P. J.;Brownstein, J. R.;Burden, A.;Burtin, E.;Busca, N. G.;Cai, Z.;Capozzi, D.;Rosell, A. C.;Carr, M. A.;Carrera, R.;Chambers, K. C.;Chaplin, W. J.;Chen, Y. C.;Chiappini, C.;Chojnowski, S. D.;Chuang, C. H.;Clerc, N.;Comparat, J.;Covey, K.;Croft, R. A. C.;Cuesta, A. J.;Cunha, K.;da Costa, L. N.;Da Rio, N.;Davenport, J. R. A.;Dawson, K. S.;De Lee, N.;Delubac, T.;Deshpande, R.;Dhital, S.;Dutra-Ferreira, L.;Dwelly, T.;Ealet, A.;Ebelke, G. L.;Edmondson, E. M.;Eisenstein, D. J.;Ellsworth, T.;Elsworth, Y.;Epstein, C. R.;Eracleous, M.;Escoffier, S.;Esposito, M.;Evans, M. L.;Fan, X. H.;Fernandez-Alvar, E.;Feuillet, D.;Ak, N. F.;Finley, H.;Finoguenov, A.;Flaherty, K.;Fleming, S. W.;Font-Ribera, A.;Foster, J.;Frinchaboy, P. M.;Galbraith-Frew, J. G.;Garcia, R. A.;Garcia-Hernandez, D. A.;Perez, A. E. G.;Gaulme, P.;Ge, J.;Genova-Santos, R.;Georgakakis, A.;Ghezzi, L.;Gillespie, B. A.;Girardi, L.;Goddard, D.;Gontcho, S. G. A.;Hernandez, J. I. G.;Grebel, E. K.;Green, P. J.;Grieb, J. N.;Grieves, N.;Gunn, J. E.;Guo, H.;Harding, P.;Hasselquist, S.;Hawley, S. L.;Hayden, M.;Hearty, F. R.;Hekker, S.;Ho, S.;Hogg, D. W.;Holley-Bockelmann, K.;Holtzman, J. A.;Honscheid, K.;Huber, D.;Huehnerhoff, J.;Ivans, II;Jiang, L. H.;Johnson, J. A.;Kinemuchi, K.;Kirkby, D.;Kitaura, F.;Klaene, M. A.;Knapp, G. R.;Kneib, J. P.;Koenig, X. P.;Lam, C. R.;Lan, T. W.;Lang, D. T.;Laurent, P.;Le Goff, J. M.;Leauthaud, A.;Lee, K. G.;Lee, Y. S.;Licquia, T. C.;Liu, J.;Long, D. C.;Lopez-Corredoira, M.;Lorenzo-Oliveira, D.;Lucatello, S.;Lundgren, B.;Lupton, R. H.;Mack, C. E.;Mahadevan, S.;Maia, M. A. G.;Majewski, S. R.;Malanushenko, E.;Malanushenko, V.;Manchado, A.;Manera, M.;Mao, Q. Q.;Maraston, C.;Marchwinski, R. C.;Margala, D.;Martell, S. L.;Martig, M.;Masters, K. L.;Mathur, S.;McBride, C. K.;McGehee, P. M.;McGreer, I. D.;McMahon, R. G.;Menard, B.;Menzel, M. L.;Merloni, A.;Meszaros, S.;Miller, A. A.;Miralda-Escude, J.;Miyatake, H.;Montero-Dorta, A. D.;More, S.;Morganson, E.;Morice-Atkinson, X.;Morrison, H. L.;Mosser, B.;Muna, D.;Myers, A. D.;Nandra, K.;Newman, J. A.;Neyrinck, M.;Nguyen, D. C.;Nichol, R. C.;Nidever, D. L.;Noterdaeme, P.;Nuza, S. E.;O'Connell, J. E.;O'Connell, R. W.;O'Connell, R.;Ogando, R. L. C.;Olmstead, M. D.;Oravetz, A. E.;Oravetz, D. J.;Osumi, K.;Owen, R.;Padgett, D. L.;Padmanabhan, N.;Paegert, M.;Palanque-Delabrouille, N.;Pan, K. K.;Parejko, J. K.;Paris, I.;Park, C.;Pattarakijwanich, P.;Pellejero-Ibanez, M.;Pepper, J.;Percival, W. J.;Perez-Fournon, I.;Perez-Rafols, I.;Petitjean, P.;Pieri, M. M.;Pinsonneault, M. H.;de Mello, G. F. P.;Prada, F.;Prakash, A.;Price-Whelan, A. M.;Protopapas, P.;Raddick, M. J.;Rahman, M.;Reid, B. A.;Rich, J.;Rix, H. W.;Robin, A. C.;Rockosi, C. M.;Rodrigues, T. S.;Rodriguez-Torres, S.;Roe, N. A.;Ross, A. J.;Ross, N. P.;Rossi, G.;Ruan, J. J.;Rubino-Martin, J. A.;Rykoff, E. S.;Salazar-Albornoz, S.;Salvato, M.;Samushia, L.;Sanchez, A. G.;Santiago, B.;Sayres, C.;Schiavon, R. P.;Schlegel, D. J.;Schmidt, S. J.;Schneider, D. P.;Schultheis, M.;Schwope, A. D.;Scoccola, C. G.;Scott, C.;Sellgren, K.;Seo, H. J.;Serenelli, A.;Shane, N.;Shen, Y.;Shetrone, M.;Shu, Y. P.;Aguirre, V. S.;Sivarani, T.;Skrutskie, M. F.;Slosar, A.;Smith, V. V.;Sobreira, F.;Souto, D.;Stassun, K. G.;Steinmetz, M.;Stello, D.;Strauss, M. A.;Streblyanska, A.;Suzuki, N.;Swanson, M. E. C.;Tan, J. C.;Tayar, J.;Terrien, R. C.;Thakar, A. R.;Thomas, D.;Thomas, N.;Thompson, B. A.;Tinker, J. L.;Tojeiro, R.;Troup, N. W.;Vargas-Magana, M.;Vazquez, J. A.;Verde, L.;Viel, M.;Vogt, N. P.;Wake, D. A.;Wang, J.;Weaver, B. A.;Weinberg, D. H.;Weiner, B. J.;White, M.;Wilson, J. C.;Wisniewski, J. P.;Wood-Vasey, W. M.;Yeche, C.;York, D. G.;Zakamska, N. L.;Zamora, O.;Zasowski, G.;Zehavi, I.;Zhao, G. B.;Zheng, Z.;Zhou, X.;Zhou, Z. M.;Zou, H.;Zhu, G. T

Elevated serum homocysteine levels have differential gender-specific associations with motor and cognitive states in Parkinson’s disease

Background: Studies attempting to elucidate an association between homocysteine and symptom progression in Parkinson’s disease (PD) have had largely discrepant findings. This study aimed to investigate elevated serum homocysteine levels and symptom progression in a cohort of PD patients. Methods: Serum homocysteine, folate, and vitamin B12 levels were measured in 205 people with PD and 78 age-matched healthy controls. People with Parkinson’s disease underwent a battery of clinical assessments to evaluate symptom severity, including motor (MDS-UPDRS) and cognitive (ACE-R) assessments. Multivariate generalized linear models were created, controlling for confounding variables, and were used to determine whether serum markers are associated with various symptom outcome measures. Results; People with Parkinson’s disease displayed significantly elevated homocysteine levels (p\u3c0.001), but not folate or vitamin B12 levels, when compared to healthy controls. A significant positive correlation between homocysteine and MDS-UPDRS III score was identified in males with Parkinson’s disease (rs=0.319, p\u3c0.001), but not in females, whereas a significant negative correlation between homocysteine levels and total ACE-R score was observed in females with Parkinson’s disease (rs=−0.449, p\u3c0.001), but not in males. Multivariate general linear models confirmed that homocysteine was significantly predictive of MDS-UPDRSIII score in male patients (p = 0.004) and predictive of total ACE-R score in female patients (p = 0.021). Conclusion: Elevated serum homocysteine levels are associated with a greater motor impairment in males with Parkinson’s disease and poorer cognitive performance in females with Parkinson’s disease. Our gender specific findings may help to explain previous discrepancies in the literature surrounding the utility of homocysteine as a biomarker in PD

Tyrosine Phosphorylation of Tau by the Src Family Kinases Lck and Fyn

<p>Abstract</p> <p>Background</p> <p>Tau protein is the principal component of the neurofibrillary tangles found in Alzheimer's disease, where it is hyperphosphorylated on serine and threonine residues, and recently phosphotyrosine has been demonstrated. The Src-family kinase Fyn has been linked circumstantially to the pathology of Alzheimer's disease, and shown to phosphorylate Tyr18. Recently another Src-family kinase, Lck, has been identified as a genetic risk factor for this disease.</p> <p>Results</p> <p>In this study we show that Lck is a tau kinase. <it>In vitro</it>, comparison of Lck and Fyn showed that while both kinases phosphorylated Tyr18 preferentially, Lck phosphorylated other tyrosines somewhat better than Fyn. In co-transfected COS-7 cells, mutating any one of the five tyrosines in tau to phenylalanine reduced the apparent level of tau tyrosine phosphorylation to 25-40% of that given by wild-type tau. Consistent with this, tau mutants with only one remaining tyrosine gave poor phosphorylation; however, Tyr18 was phosphorylated better than the others.</p> <p>Conclusions</p> <p>Fyn and Lck have subtle differences in their properties as tau kinases, and the phosphorylation of tau is one mechanism by which the genetic risk associated with Lck might be expressed pathogenically.</p

Elevated HDL Levels Linked to Poorer Cognitive Ability in Females With Parkinson’s Disease

IntroductionCholesterol levels have been associated with age-related cognitive decline, however, such an association has not been comprehensively explored in people with Parkinson’s disease (PD). To address this uncertainty, the current cross-sectional study examined the cholesterol profile and cognitive performance in a cohort of PD patients.MethodsCognitive function was evaluated using two validated assessments (ACE-R and SCOPA-COG) in 182 people with PD from the Australian Parkinson’s Disease Registry. Total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and Triglyceride (TRG) levels were examined within this cohort. The influence of individual lipid subfractions on domain-specific cognitive performance was investigated using covariate-adjusted generalised linear models.ResultsFemales with PD exhibited significantly higher lipid subfraction levels (TC, HDL, and LDL) when compared to male counterparts. While accounting for covariates, HDL levels were strongly associated with poorer performance across multiple cognitive domains in females but not males. Conversely, TC and LDL levels were not associated with cognitive status in people with PD.ConclusionHigher serum HDL associates with poorer cognitive function in females with PD and presents a sex-specific biomarker for cognitive impairment in PD

TLR-4 ligation of dendritic cells is sufficient to drive pathogenic T cell function in experimental autoimmune encephalomyelitis

<p>Abstract</p> <p>Background</p> <p>Experimental autoimmune encephalomyelitis (EAE) depends on the initial activation of CD4⁺ T cells responsive to myelin autoantigens. The key antigen presenting cell (APC) population that drives the activation of naïve T cells most efficiently is the dendritic cell (DC). As such, we should be able to trigger EAE by transfer of DC that can present the relevant autoantigen(s). Despite some sporadic reports, however, models of DC-driven EAE have not been widely adopted. We sought to test the feasibility of this approach and whether activation of the DC by toll-like receptor (TLR)-4 ligation was a sufficient stimulus to drive EAE.</p> <p>Findings</p> <p>Host mice were seeded with myelin basic protein (MBP)-reactive CD4+ T cells and then were injected with DC that could present the relevant MBP peptide which had been exposed to lipopolysaccharide as a TLR-4 agonist. We found that this approach induced robust clinical signs of EAE.</p> <p>Conclusions</p> <p>DC are sufficient as APC to effectively drive the differentiation of naïve myelin-responsive T cells into autoaggressive effector T cells. TLR-4-stimulation can activate the DC sufficiently to deliver the signals required to drive the pathogenic function of the T cell. These models will allow the dissection of the molecular requirements of the initial DC-T cell interaction in the lymphoid organs that ultimately leads to autoimmune pathology in the central nervous system.</p

Modulation of enhancer looping and differential gene targeting by Epstein-Barr virus transcription factors directs cellular reprogramming

Epstein-Barr virus (EBV) epigenetically reprogrammes B-lymphocytes to drive immortalization and facilitate viral persistence. Host-cell transcription is perturbed principally through the actions of EBV EBNA 2, 3A, 3B and 3C, with cellular genes deregulated by specific combinations of these EBNAs through unknown mechanisms. Comparing human genome binding by these viral transcription factors, we discovered that 25% of binding sites were shared by EBNA 2 and the EBNA 3s and were located predominantly in enhancers. Moreover, 80% of potential EBNA 3A, 3B or 3C target genes were also targeted by EBNA 2, implicating extensive interplay between EBNA 2 and 3 proteins in cellular reprogramming. Investigating shared enhancer sites neighbouring two new targets (WEE1 and CTBP2) we discovered that EBNA 3 proteins repress transcription by modulating enhancer-promoter loop formation to establish repressive chromatin hubs or prevent assembly of active hubs. Re-ChIP analysis revealed that EBNA 2 and 3 proteins do not bind simultaneously at shared sites but compete for binding thereby modulating enhancer-promoter interactions. At an EBNA 3-only intergenic enhancer site between ADAM28 and ADAMDEC1 EBNA 3C was also able to independently direct epigenetic repression of both genes through enhancer-promoter looping. Significantly, studying shared or unique EBNA 3 binding sites at WEE1, CTBP2, ITGAL (LFA-1 alpha chain), BCL2L11 (Bim) and the ADAMs, we also discovered that different sets of EBNA 3 proteins bind regulatory elements in a gene and cell-type specific manner. Binding profiles correlated with the effects of individual EBNA 3 proteins on the expression of these genes, providing a molecular basis for the targeting of different sets of cellular genes by the EBNA 3s. Our results therefore highlight the influence of the genomic and cellular context in determining the specificity of gene deregulation by EBV and provide a paradigm for host-cell reprogramming through modulation of enhancer-promoter interactions by viral transcription factors